These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 10829266)

  • 1. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2000 Jun; 14(2):463-74. PubMed ID: 10829266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of a vancomycin-resistant Enterococcus faecium ventricular drain infection with quinupristin/dalfopristin and review of the literature.
    Tan TY; Pitman I; Penrose-Stevens A; Simpson BA; Flanagan PG
    J Infect; 2000 Jul; 41(1):95-7. PubMed ID: 11041712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
    Manfredi R
    Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ; Hershberger E; Moldovan T; Grucz RG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.
    Noskin GA; Siddiqui F; Stosor V; Hacek D; Peterson LR
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2059-62. PubMed ID: 10428937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinupristin-dalfopristin.
    Bryson HM; Spencer CM
    Drugs; 1996 Sep; 52(3):406-15. PubMed ID: 8875130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: emerging problems and new prospects for management.
    Noskin GA
    Ann Acad Med Singap; 2001 May; 30(3):320-31. PubMed ID: 11455748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Other antimicrobials (linezolid, quinupristin/dalfopristin)].
    Yamaguchi K; Ohno A
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():756-61. PubMed ID: 12722312
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
    Tünger A; Aydemir S; Uluer S; Cilli F
    Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
    Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
    Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antibiotics for gram positive infections: linezolid and combination quinapristin/dalfopristin.
    MacConnachie AM
    Intensive Crit Care Nurs; 1999 Aug; 15(4):239-41. PubMed ID: 10786510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
    Lamb HM; Figgitt DP; Faulds D
    Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
    Luh KT; Hsueh PR; Teng LJ; Pan HJ; Chen YC; Lu JJ; Wu JJ; Ho SW
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3374-80. PubMed ID: 11083643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinupristin-dalfopristin and linezolid: evidence and opinion.
    Eliopoulos GM
    Clin Infect Dis; 2003 Feb; 36(4):473-81. PubMed ID: 12567306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
    von Eiff C; Peters G
    J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy--a status report.
    Batts DH; Lavin BS; Eliopoulos GM
    Curr Clin Top Infect Dis; 2001; 21():227-51. PubMed ID: 11572153
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    Antimicrob Agents Chemother; 2003 Jan; 47(1):337-41. PubMed ID: 12499210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the oxazolidinone antibiotics.
    Abdel-Rahman SM; Kearns GL
    Pediatr Infect Dis J; 1999 Dec; 18(12):1101-2. PubMed ID: 10608633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.